pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
1,124
stories
14d
2026 IPO blitz continues with 4 new biotech filings
biospace
14d
Novartis secures new radioligand in $900M deal as competition strengthens
fiercebiotech
14d
STAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and more
stat
14d
Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition
fiercebiotech
14d
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
fiercebiotech
14d
Vertex’s midstage data amplify kidney disease market opportunity
fiercebiotech
14d
Siemens Healthineers and Novo team up on fatty liver disease awareness, testing
fiercebiotech
14d
STAT+: Ohio governor’s race is a battle over Covid, health costs, and trust in science
stat
14d
Cordis’ sirolimus drug-coated balloon earns FDA approval as a breakthrough device
fiercebiotech
14d
Beacon eye gene therapy hits mark in late-stage study
biopharma dive
14d
STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators
stat
14d
Novo talks up drug launches in effort to win back investors
biopharma dive
14d
FDA approves ataxia-telangiectasia drug; Alkermes reports ADHD data
endpoints
14d
Novo offers low-dose CagriSema data as approval decision looms
endpoints
14d
STAT+: Lilly’s breast cancer combo wins approval
stat
14d
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
15d
Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
biopharma dive
15d
How J&J paved the way for Compass’ coming psychedelic drug launch
biopharma dive
15d
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
15d
Opinion: STAT+: The NIH budget should be $100 billion per year
stat
15d
Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
fiercebiotech
15d
Citing Replimune approval, experts say localized cancer meds could redefine care
biospace
15d
Mikhail, Davis on board with regulatory framework tailored to rare disease therapies
biospace
15d
Beyond Random Integration: Transposase cell line development shortening timeline & boosting titers
biospace
15d
STAT+: Radiopharma companies merge after one receives surprise FDA rejection
stat
16d
Beacon lights path to FDA approval with pivotal trial win for rare vision loss gene therapy
fiercebiotech
17d
FDA approves Lilly's oral SERD combo for second-line breast cancer therapy
endpoints
17d
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
17d
CHMP backs Novo’s hemophilia A drug and seven other medicines
endpoints
17d
Electra lights up with $350M IPO for pivotal immune-disease drug development
biospace
← prev
page 5 of 38
next →
